Published in Gene Therapy Weekly, October 25th, 1999
E.S. Stavridi and colleagues from the Wistar Institute, Pennsylvania, studied protein interactions that interfere with p53-based cancer gene therapies. Their results were presented in a recent issue of Protein Science ("Change in Oligomerization Specificity of the p53 Tetramerization Domain by Hydrophobic Amino Acid Substitutions," Protein Science, September 1999;8(9):1773-1779).
"The tumor suppressor function of the wild-type p53 protein is transdominantly inhibited by tumor-derived mutant p53 proteins," wrote Stavridi et al. "Such transdominant...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (1999-10-25)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.